# EDGAR Filing Document

**Accession Number:** 0001849380
**File Stem:** 0001493152-25-021265
**Filing Date:** 2025-11
**Character Count:** 115390
**Document Hash:** 9487302a2195c5346f9b723e28abfd4f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021265.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001493152-25-021265

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20251107

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OneMedNet Corp
- **CENTRAL INDEX KEY:** 0001849380
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 862076743
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40386
- **FILM NUMBER:** 251462736

**BUSINESS ADDRESS:**
- **STREET 1:** TRIDENT COURT, 1 OAKCROFT ROAD
- **STREET 2:** CHESSINGTON
- **CITY:** SURREY
- **STATE:** X0
- **ZIP:** KT9 1BD
- **BUSINESS PHONE:** 011-44-208-090-2009

**MAIL ADDRESS:**
- **STREET 1:** TRIDENT COURT, 1 OAKCROFT ROAD
- **STREET 2:** CHESSINGTON
- **CITY:** SURREY
- **STATE:** X0
- **ZIP:** KT9 1BD

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Data Knights Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210304

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

---

| |
|:---|
| **OneMedNet Corporation** |
| (Name of Registrant as Specified in its Charter) |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |

---

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required. <br> ☐ Fee paid previously with preliminary materials. <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

![](formdef14a_001.jpg)

**6385 Old Shady Oak Road, Suite 250**

**Eden Prairie, Minnesota 55344**

November 7, 2025

Dear Stockholder:

We cordially invite you to attend the 2025 Annual Meeting of Stockholders of OneMedNet Corporation (the "Annual Meeting"). The Annual Meeting will be held on Wednesday, December 17, 2025, at 11:00 a.m. Central Time. The Annual Meeting will be held entirely online live via audio webcast. You will be able to attend and participate in the Annual Meeting online by visiting <u>https://www.cstproxy.com/onemednet/2025</u>, where you will be able to listen to the Annual Meeting live, submit questions, and vote.

You will find important information about the matters to be voted on at the Annual Meeting in the accompanying Notice of Annual Meeting of Stockholders and Proxy Statement. We are sending most of our stockholders a one-page Notice of Internet Availability of Proxy Materials (the "Notice") instead of sending them a full set of printed materials. The Notice tells you how to access and review the important information contained in the proxy materials on the internet and how to request to receive a printed copy of our proxy materials. The Notice also tells you how to vote on the internet prior to the Annual Meeting.

Your vote is important. We hope you will attend the Annual Meeting. We encourage you to review the proxy materials and vote as soon as possible. You may submit your vote three ways: first, as indicated above, you may vote on the internet prior to the meeting; second, you may vote by mail, if you timely request to receive printed copies of these proxy materials in the mail; finally, you may vote your shares electronically during the Annual Meeting. Details about how to attend the Annual Meeting online and how to submit questions and cast your votes are posted at <u>https://www.cstproxy.com/onemednet/2025</u> and can be found in the section entitled "General Information About the Annual Meeting—How can I attend and vote at the Annual Meeting?" in the proxy statement.

---

| |
|:---|
| Very truly yours,<br>|
| /s/ Dr. Jeffrey Yu<br>|
| Dr. Jeffrey Yu <br> Chairman of the Board of Directors |

---

![](formdef14a_001.jpg)

**6385 Old Shady Oak Road, Suite 250**

**Eden Prairie, Minnesota 55344**

**NOTICE OF ANNUAL MEETING OF STOCKHOLDERS**

---

| | |
|:---|:---|
| **Annual Meeting Date** | Wednesday, December 17, 2025 |
| **Time**<br>| 11:00 a.m. Central Time |
| **Place**<br>| Via live webcast at <u>https://www.cstproxy.com/onemednet/2025</u> |

---

---

| | | |
|:---|:---|:---|
| **Items of Business** | (1) | To elect two Class II directors nominated by our Board of Directors to serve three-year terms expiring at our 2028 Annual Meeting of Stockholders; |
|  | (2) | To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2025; and |
|  | (3) | To transact any other business that properly comes before the Annual Meeting and any adjournment or postponement of the Annual Meeting. |

---

---

| | |
|:---|:---|
| **Record Date** | Only holders of record of our common stock on October 23, 2025, are entitled to receive notice of and to vote at the Annual Meeting and any postponement or adjournment of the Annual Meeting.<br>|
| **Voting** | Your vote is important. We encourage you to read the accompanying proxy materials and submit your vote as soon as possible. You can find information about how to cast your vote in the question-and-answer section of the accompanying proxy statement. |

---

Pursuant to rules adopted by the U.S. Securities and Exchange Commission, we have elected to provide access to our proxy materials via the internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials (the "Notice") to our stockholders entitled to notice of, and to vote at, the Annual Meeting and at any postponement or adjournment thereof. Stockholders will have the ability to access the proxy materials at <u>https://www.cstproxy.com/onemednet/2025</u> or request to receive a printed set of the proxy materials by mail or an electronic set of materials by email. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. In addition, stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis.

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS** 

**FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 17, 2025:**

**This Notice, our proxy statement, and our 2024 annual report are available at <u>https://www.cstproxy.com/onemednet/2025</u>.**

---

| |
|:---|
| By Order of the Board of Directors of OneMedNet Corporation, |
| /s/ Aaron Green |
| Aaron Green<br> Chief Executive Officer |

---

Eden Prairie, Minnesota

November 7, 2025

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [General Information About the Annual Meeting](#mj_001) | 1 |
| [Proposal 1 – Election of Class II Directors](#a_001) | 6 |
| [Proposal 2 – Ratification of the Appointment of WithumSmith+Brown, PC as our Independent Registered Public Accounting Firm](#a_002) | 10 |
| [Audit Committee Report](#a_003) | 12 |
| [Corporate Governance](#a_004) | 13 |
| [Executive Officers](#a_005) | 17 |
| [Executive Compensation](#a_006) | 18 |
| [Director Compensation](#a_007) | 21 |
| [Security Ownership of Certain Beneficial Owners and Management](#a_008) | 22 |
| [Equity Compensation Plan Information](#a_009) | 24 |
| [Certain Relationships and Related-Person Transactions](#a_010) | 25 |
| [Householding](#a_011) | 27 |
| [Stockholder Proposals](#a_012) | 27 |
| [Annual Report on Form 10-K and Other SEC Filings](#a_013) | 27 |
| [Other Matters](#a_014) | 28 |

---

![](formdef14a_001.jpg)

**ONEMEDNET CORPORATION**

**6385 Old Shady Oak Road, Suite 250**

**Eden Prairie, Minnesota 55344**

**(800) 918-7189**

**PROXY STATEMENT**

**2025 ANNUAL MEETING OF STOCKHOLDERS**

**INFORMATION ABOUT SOLICITATION AND VOTING**

The Board of Directors (the "Board" or "Board of Directors") of OneMedNet Corporation (the "Company," "OneMedNet," "we," "us" or "our") is providing these materials to you in connection with our 2025 Annual Meeting of Stockholders (the "Annual Meeting"), which will take place on Wednesday, December 17, 2025 at 11:00 a.m., Central Time. The Annual Meeting will be held virtually at <u>www.cstproxy.com/onemednet/2025</u>, where you will be able to listen to the meeting live, submit questions, and vote. We believe that holding the Annual Meeting virtually is an important step to enhancing accessibility to the meeting and reducing the carbon footprint of our activities. This proxy statement and the accompanying other proxy materials will be first made available to stockholders on or about November 7, 2025.

**GENERAL INFORMATION ABOUT THE ANNUAL MEETING**

**Why did I receive these proxy materials?**

We are providing these proxy materials to you in connection with the solicitation by the Board of Directors (the "Board") of OneMedNet Corporation, a Delaware corporation, of proxies to be voted at our 2025 Annual Meeting of Stockholders (the "Annual Meeting").

The Annual Meeting will be held on Wednesday, December 17, 2025, at 11:00 a.m. Central Time, online at <u>https://www.cstproxy.com/onemednet/2025</u>. The Annual Meeting will be a completely virtual meeting conducted via live audio webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting <u>https://www.cstproxy.com/onemednet/2025</u> and entering your control number included in your Notice of Internet Availability of Proxy Materials (the "Notice"), on your proxy card, or on the instructions that accompanied your proxy materials. If you lose your control number, you may join the Annual Meeting as a "Guest," but you will not be able to vote, ask questions, or access the list of stockholders as of the close of business on the Record Date (as defined below). Only stockholders with a valid control number will be able to attend the Annual Meeting and vote, ask questions, and access the list of stockholders as of the close of business on the Record Date.

**What matters will be voted on at the Annual Meeting?**

We will ask stockholders to vote on the following matters at the Annual Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;(1) To
 elect two Class II directors nominated by our Board to serve three-year terms expiring
 at our 2028 Annual Meeting of Stockholders (Proposal 1);

&nbsp;&nbsp;&nbsp;&nbsp;(2) To
 ratify the appointment of WithumSmith+Brown, PC ("Withum") as our independent
 registered public accounting firm for the year ending December 31, 2025 (Proposal 2); and

&nbsp;&nbsp;&nbsp;&nbsp;(3) To
 transact any other business that properly comes before the Annual Meeting and any adjournment
 or postponement of the Annual Meeting.

**Who can vote?**

Stockholders of record at the close of business on the record date of October 23, 2025 (the "Record Date"), are entitled to receive notice of and to vote at the Annual Meeting. As of the Record Date, we had 51,157,069 shares of common stock issued and outstanding. Each share is entitled to one vote on each item voted on at the Annual Meeting.

A list of stockholders entitled to vote at the Annual Meeting will be available for inspection by any stockholder for the 10 days prior to the Annual Meeting at <u>https://www.cstproxy.com/onemednet/2025</u>. In addition, the list of stockholders will also be available during the Annual Meeting through the Annual Meeting website for those stockholders who choose to attend.

To attend and participate in the Annual Meeting, you will need the control number included in your Notice, on your proxy card, or on the instructions that accompanied your proxy materials. If your shares are held in "street name," you should contact your broker, bank, or other nominee to obtain your control number or otherwise vote through the broker, bank, or other nominee. If you lose your control number, you may join the Annual Meeting as a "Guest," but you will not be able to vote, ask questions, or access the list of stockholders as of the close of business on the Record Date. Only stockholders with a valid control number will be able to attend the Annual Meeting and vote, ask questions, and access the list of stockholders as of the close of business on the Record Date. The Annual Meeting webcast will begin promptly at 11:00 a.m. Central Time. We encourage you to access the Annual Meeting prior to the start time. Online check-in will begin at 10:30 a.m. Central Time. You should allow ample time for the check-in procedures.

**What is the difference between a stockholder of record and a beneficial holder?**

Most of our stockholders hold their shares through a broker, bank, or other nominee rather than directly in their own name. There are some important distinctions between shares held of record and those owned beneficially.

**Stockholder of Record**

If your shares are registered directly in your name with our transfer agent, Continental Stock Transfer & Trust Company ("Continental"), you are the stockholder of record for those shares and are receiving proxy materials directly from us. As the stockholder of record, you have the right to grant your voting proxy directly to us or to vote online at the Annual Meeting.

**Beneficial Holder**

If your shares are held in a stock brokerage account, by a bank, or other nominee (commonly referred to as being held in "street name"), you are the beneficial holder of those shares. Your broker, bank or other nominee is the stockholder of record and has forwarded proxy materials to you as beneficial holder. As the beneficial holder, you have the right to direct your broker, bank, or other nominee how to vote your shares and are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares online at the Annual Meeting unless you have requested and obtained a valid proxy from your bank, broker or other nominee.

**How do I vote?**

**Stockholder of Record**

If you are a stockholder of record, you can vote on the internet prior to the Annual Meeting by following the instructions you received from us in the mail or by email. If you requested to receive a full set of proxy materials in the mail, you also can vote by mail using the proxy card included with the materials. Finally, you can vote online at the Annual Meeting by attending the Annual Meeting online and following the instructions posted at <u>https://www.cstproxy.com/onemednet/2025</u>.

**Beneficial Holder**

If you are a beneficial holder, you can vote prior to the Annual Meeting by following the voting instructions you received from your broker, bank, or other nominee in the mail or by email. If you have not received this information from your broker, bank, or other nominee, please contact them as soon as possible.

If you do not give your broker, bank, or other nominee instructions as to how to vote, under stock exchange rules, your broker, bank, or other nominee may not vote your shares on any of the proposals without your instructions, other than the ratification of the appointment of our independent registered public accounting firm. Please be sure to return your voting instructions to your broker, bank, or other nominee so that your vote is counted. The voting deadlines and availability of internet voting for beneficial owners of shares held in "street name" will depend on the voting processes of the organization that holds your shares. Therefore, we urge you to carefully review and follow the voting instructions card and any other materials that you receive from that organization.

As the beneficial holder, you may attend the Annual Meeting as a "Guest" at <u>https://www.cstproxy.com/onemednet/2025</u>, but you may not vote your shares online or otherwise participate at the Annual Meeting unless you have requested and obtained a valid proxy from your bank, broker or other nominee.

**Multiple Holdings**

If you hold shares both as a stockholder of record and as a beneficial holder, **you must vote separately** for each set of shares.

**How can I attend and vote at the Annual Meeting?**

This year's Annual Meeting will be held entirely online live via audio webcast. Any stockholder can attend the Annual Meeting live online at <u>https://www.cstproxy.com/onemednet/2025</u>. If you were a stockholder of record as of the Record Date and you have your control number included in your Notice, on your proxy card or on the instructions that accompanied your proxy materials, you can vote at the Annual Meeting.

A summary of the information you need to attend the Annual Meeting online is provided below:

● To attend and participate in the Annual Meeting, you will need the control number included in your Notice, on your proxy card, or on the instructions that accompanied your proxy materials.

● The Annual Meeting webcast will begin promptly at 11:00 a.m. Central Time. We encourage you to access the Annual Meeting prior to the start time. Online check-in will begin at 10:30 a.m. Central Time, and you should allow ample time for the check-in procedures.

● The virtual Annual Meeting platform is fully supported across browsers (Internet Explorer, Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets, and cell phones) running the most updated version of applicable software and plugins. Participants should ensure that they have a strong internet connection wherever they intend to participate in the Annual Meeting. Participants should also give themselves plenty of time to log in and ensure that they can hear streaming audio prior to the start of the Annual Meeting.

● Instructions on how to attend and participate via the internet, including how to demonstrate proof of stock ownership, are posted at <u>https://www.cstproxy.com/onemednet/2025</u>.

● Assistance with questions regarding how to attend and participate via the internet will be provided at <u>https://www.cstproxy.com/onemednet/2025</u> on the day of the Annual Meeting.

● Questions pertinent to Annual Meeting matters will be answered during the Annual Meeting, subject to time constraints. Questions regarding personal matters, including those related to employment, product or service issues, or suggestions for product innovations, are not pertinent to Annual Meeting matters and therefore will not be answered. Any questions pertinent to Annual Meeting matters that cannot be answered during the meeting due to time constraints will be posted online and answered at the "Investor Relations" section of our website at https://www.onemednet.com/investor-relations/. The questions and answers will be available as soon as practical after the Annual Meeting and will remain available until one week after posting.

If your shares are held in "street name," you should direct your bank, broker or other nominee on how to vote your shares according to the voting instructions your bank, broker or other nominee has provided to you, or, if you wish to vote at the Annual Meeting, you must contact your bank, broker, or other nominee to obtain a valid proxy. Without a valid proxy from your bank, broker or other nominee, you may join the Annual Meeting as a "Guest," but you will not be able to vote, ask questions, or access the list of stockholders as of the close of business on the Record Date.

**What if during the check-in time or during the Annual Meeting I have technical difficulties or trouble accessing the virtual Annual Meeting website?**

We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual Annual Meeting website. If you encounter any difficulties accessing the virtual Annual Meeting website during the check-in or meeting time, please call the technical support number that will be posted on the Annual Meeting login page.

**Can I change or revoke my vote?**

If you are a stockholder of record, you may change your vote at any time prior to the vote at the Annual Meeting by taking any of the following actions:

● submitting a new proxy with a later date using any of the available methods described above;

● providing a written revocation to our Corporate Secretary; or

● voting online at the Annual Meeting by following the instructions at <u>https://www.cstproxy.com/onemednet/2025</u>.

If you are a beneficial holder, you may change your vote by submitting new voting instructions to your bank, broker, or other nominee following the instructions they provided to you. If you have received a valid proxy from your bank, broker or other nominee, you may also vote online at the Annual Meeting, which will have the effect of revoking any previously submitted voting instructions.

Whether you are a stockholder of record or a beneficial owner of shares held in street name, your attendance at the Annual Meeting online will not, by itself, automatically revoke your proxy.

**What is the quorum requirement for the Annual Meeting?**

A quorum of stockholders is necessary for any action to be taken at the Annual Meeting (other than adjournment or postponement of the Annual Meeting). A quorum exists if stockholders holding a majority of the voting power of all outstanding shares of our common stock entitled to vote are present at the Annual Meeting in person, or by means of remote communication, or by proxy. If you submit a properly completed proxy, even if you abstain from voting, your shares will be counted for purposes of determining the presence of a quorum. Broker non-votes (described below) also will be counted for purposes of determining the presence of a quorum if the broker, bank or other nominee uses its discretionary authority to vote on at least one routine matter under stock exchange rules.

**How will my shares be voted at the Annual Meeting?**

Your shares will be voted in accordance with your properly submitted instructions.

**Stockholders of Record**

If you are a stockholder of record and you submit a duly executed proxy but do not include voting instructions on a matter, your shares will be voted in favor of each of the nominees named in Proposal 1 and in favor of Proposal 2, in accordance with the recommendations of our Board. If any other matters are properly presented for a vote at the Annual Meeting or any adjournment or postponement thereof, your shares will be voted in the discretion of the named proxies.

**Beneficial Holders and Broker Non-Votes**

If you are a beneficial holder and you do not provide voting instructions to your bank, broker, or other nominee, that organization will determine if it has the discretionary authority to vote your shares on the particular matter. Under stock exchange rules, these organizations have the discretion to vote your shares on routine matters, such as the ratification of the appointment of Withum as our independent registered public accounting firm for 2025 (Proposal 2). However, they do not have the discretion to vote your shares on non-routine matters, including the other proposal up for a vote (Proposal 1). The unvoted shares are called "broker non-votes." Shares that constitute broker non-votes are considered present for purposes of determining a quorum but are not considered entitled to vote or votes cast on the particular matter.

**What are the voting requirements for each matter?**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Proposal** | **Vote Required** | **Effect of Abstentions** | **Broker Discretionary Voting Allowed** | **Effect of Broker Non-Vote** |
| *Proposal 1 – Election of Directors* | Plurality of the Votes Cast | No effect | No | No effect |
| *Proposal 2 – Ratification of our independent registered public accounting firm for the year ending December 31, 2025* | Majority of Votes Cast | No effect | Yes | Not applicable |

---

**What are the recommendations of the Board?**

Our Board recommends that you vote:

● "**FOR**" the Class II directors nominated by our Board to serve three-year terms expiring at our 2028 Annual Meeting of Stockholders (Proposal 1); and

● "**FOR**" the ratification of the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2025 (Proposal 2).

Any properly authorized proxy as to which no instructions are given will be voted in accordance with the foregoing recommendations.

**Who will pay the costs of soliciting votes for the Annual Meeting?**

We will pay all costs of soliciting proxies. The solicitation may be made personally or by mail, phone, email, or other electronic communication. In addition, our officers, directors, and employees, without additional compensation, may solicit proxies. The solicitation may be made personally or by mail, phone, email, or other electronic communication. We will send proxy materials or additional soliciting materials to banks, brokers, other institutions, nominees, and fiduciaries. These organizations will then forward the materials to the beneficial holders of our shares. On request, we will reimburse these organizations for their reasonable expenses in forwarding these materials.

**Who will count the votes?**

Continental has been appointed as the inspector of elections for the Annual Meeting. A representative of Continental will tabulate votes cast by proxy or electronically before and during the meeting.

**How can I find the results of the voting after the Annual Meeting?**

We will announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.

**PROPOSAL 1 – ELECTION OF CLASS II DIRECTORS**

Our Board currently consists of nine directors divided into three classes, designated as Class I, Class II, and Class III. In accordance with our Amended and Restated Bylaws (our "Bylaws") and Third Amended and Restated Certificate of Incorporation (our "Certificate of Incorporation"), the number of directors of the Board is fixed exclusively by the Board from time to time. The directors are divided as evenly as possible into the three classes. The classes of directors serve for staggered three-year terms, with their current terms ending at the Annual Meeting of Stockholders in the following years: Class I directors – 2027; Class II directors – 2025; and Class III directors – 2026.

The Class II directors elected at the Annual Meeting will serve until the 2028 Annual Meeting of Stockholders. Directors are elected by a plurality, with the two nominees obtaining the most votes being elected. Because there is no minimum vote required, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome. Under the plurality vote standard, any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the election of directors. Cumulative voting is not permitted in the election of directors. Each nominee this year is a current director.

Our nominees for the Class II directorship are Robert Golden and Andrew Zeinfeld, both of whom are current directors. The Board nominated Mr. Golden and Mr. Zeinfeld based on the recommendation of the Nominating and Corporate Governance Committee. In considering the nominees for the Class II directorship, the Nominating and Corporate Governance Committee assessed the qualifications of each nominee, all of whom are current directors, before making a recommendation regarding their nomination to the Board. Each nominee has consented to serve as a director if elected. However, if any nominee is unable to serve, or for good cause will not serve, the persons named in the proxy intend to vote in their discretion for one or more substitutes who will be designated by the Board.

On November 6, 2025, Jair Clarke informed the Company that he would not stand for re-election at the Annual Meeting. Mr. Clarke intends to remain on the Board until the expiration of his term at the Annual Meeting, and following the Annual Meeting, he will continue to serve the Company in an advisory capacity. At the conclusion of the Annual Meeting, the size of the Board will be reduced to eight members.

Information about our directors, including our Class II director nominees, is set forth below. This information includes an overview of the director's specific experience, qualifications, and skills that assisted our Nominating and Corporate Governance Committee and Board to conclude that the individual should serve as a director. Each nominee and continuing director's age is as of November 7, 2025.

**<u>Class II Director Nominees</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Age** | **Director Since** | **Principal Occupation** |
| Robert Golden | 63 | November 2023 | Managing Partner of Cohen, Bender & Golden LLP |
| Andrew Zeinfeld | 65 | August 2024 | Managing partner of several real estate developments |

---

**Robert Golden** is an accomplished Certified Public Accountant ("CPA") with more than 30 years of experience. Mr. Golden has served as the Company's Chief Financial Officer since January 2025 and as our Corporate Secretary since September 2024. Mr. Golden has served as a member of our Board of Directors since November 2023. He previously served as our Interim Chief Financial Officer from August 2024 until his appointment as our permanent Chief Financial Officer in January 2025. Mr. Golden also serves as the Managing Partner of Cohen, Bender & Golden LLP, where he provides consulting, accounting and tax services to middle market businesses and owners since September 2015. Prior to that, from January 2013 to August 2015, Mr. Golden worked at Fenton & Ross Accountancy Corporation and, from September 2004 to December 2012, at Saffer & Flint Accountancy Corporation. From December 1989 to June 2004, Mr. Golden was at Good Swartz Brown & Berns LLP (now CohnReznick) ("GSBB"), where he served as a partner from 1994 onwards. There, Mr. Golden performed administrative duties, including overseeing the company's merger negotiations in 2000 and performed financial statement audits, reviews and income tax planning for middle market businesses and owners. While at GSBB and continuing today, Mr. Golden consults with his business clients to assist their entrepreneurial owners to better understand the financial performance of their businesses and to help them improve operational efficiencies and profitability by acting as their outside CFO. Bob also assists with structuring and negotiating financing, compensation planning, investment opportunity review, as well as merger and acquisition activities and works with wealthy families acting in a CFO-type role for their family office activities. After leaving GSBB in 2004, in addition to continuing to provide consulting services to middle-market companies, Bob was the owner and CEO of several companies in the construction and engineering field, coffee and baked goods industries and also syndicated commercial real estate acquisitions.

From September 1984 to December 1989, Mr. Golden was a CPA at Ernst & Young in Los Angeles. Apart from his experience as a CPA, Mr. Golden is currently the Chief Financial Officer of Promo Shop, Inc. & Subsidiaries, a specialty advertising promotional products multi-office distributor based in Los Angeles. Mr. Golden establishes the company's annual budget among other duties and has been in this role since January 2008. Mr. Golden is also currently the Chief Financial Officer at iKahan Media, Inc., an out of home media company specializing in digital and traditional billboards and advertisement, where he has served since September 2014. Mr. Golden is a member of the Board of Directors of Talon International, Inc. (OTCMKTS: TALN), the world's oldest and largest zipper manufacturer.

In 1984, Mr. Golden received his Bachelor of Science degree in Business Administration from the University of Southern California. Mr. Golden also holds a Certified Public Accountant certification from the California Board of Accountancy, is an Investment Advisor Representative with the SEC and is a Licensed Engineering Contractor with the California Contractors State License Board. We believe Mr. Golden is well-qualified to serve as a member of our Board of Directors due to his extensive experience as a Certified Public Accountant at numerous firms as well as his experience as an executive officer at multiple companies.

**Andrew Zeinfeld** has over 30 years of public and private sector senior management experience across a variety of industries, including retail, online, telecom, distribution and real estate. In addition to managing these various businesses, Mr. Zeinfeld also developed strategies to drive profitable growth both organically and through mergers and acquisitions.

Since June 2019, Mr. Zeinfeld has been the managing partner of several LLCs that manage his real estate developments and investment portfolio. From November 2019 through March 2023, Mr. Zeinfeld served as the Chief Executive Officer of Sunstrike International Ltd., a leading distributor of second life refurbished mobile devices and trade-in solutions within the circular economy. From 2013 through 2018, Mr. Zeinfeld also worked at Brightstar Corp. (n/k/a Likewize), an end-to-end mobile device management solutions company, where he served in various roles of increasing responsibility. We believe Mr. Zeinfeld is well-qualified to serve as a member of our Board of Directors due to his senior management experience in both the public and private sector.

**<u>Continuing Directors</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Age** | **Director Since** | **Class/Term Expiration** |
| Eric Casaburi | 51 | November 2023 | Class I/ 2027 |
| Aaron Green | 52 | March 2024 | Class I/ 2027 |
| Dr. Thomas Kosasa | 80 | November 2023 | Class I/ 2027 |
| Dr. Kenneth Alleyne | 59 | February 2025 | Class III/ 2026 |
| Sherry Coonse McCraw | 57 | October 2024 | Class III/ 2026 |
| Dr. Jeffrey Yu | 57 | November 2023 | Class III/ 2026 |

---

**Eric Casaburi** is an experienced entrepreneur and chief executive officer with a successfully demonstrated history of explosive growth in the franchising, health and wellness, food services, and real estate industries including founding and leading RetroFitness from a start-up single-gym business to a $150 million per year in sales operation while expanding its national footprint. Mr. Casaburi has founded and held positions as chief executive officer for multiple franchise brands, each having successful exits with impressive returns for investors and private equity partners. Since 2021, Mr. Casaburi has served as founder and Chief Executive Officer of Serotonin Enterprises LLC, a cutting edge Anti-Aging Health Optimization Franchise that offers a vast service menu covering all aspects of optimal health, appearance and performance. Serotonin Centers have been featured in the Franchise Times as the first franchise of its kind in the United States. Since 2019, Mr. Casaburi has served as the Chair of TIGER 21 Orlando, a group of men and women who have achieved both success and significance in their lives that helps members build the skill set to successfully transition from focused entrepreneurs to disciplined managers of wealth.

Since 2020, Mr. Casaburi has founded and operated Longevity Brands and since 2016, Mr. Casaburi founded and owns CEVD Holdings, a commercial real estate investment and management company. Mr. Casaburi developed all sales, operations, and marketing systems for both the RetroFitness fitness centers and the franchise and designed and implemented a diversified reoccurring revenue model to improve business health and value. Mr. Casaburi also founded and served as the Chief Executive Officer of Lets YO! Yogurt from 2012-2015, a self-serve yogurt and treats restaurant popularized through social media savvy, in which he franchised the business model and opened 24 restaurants in the first year and led to a successful exit to an industry private equity firm. We believe Mr. Casaburi is well-qualified to serve as a member of our Board of Directors due to his experience successfully founding and growing companies.

**Aaron Green** is a healthcare IT business transformation leader with more than 20 years of leadership experience in healthcare management, sales, strategic planning, M&A, product development, customer support and services operations. Mr. Green has served as our Chief Executive Officer and a Director since March 2024 and President since May 2023. Prior to joining OneMedNet, Mr. Green served in a variety of healthcare technology roles including most recently at Optum, a United Health Group company (NYSE: UHG), a leading healthcare technology company, as Vice President Cloud Solutions. At Optum, Mr. Green was responsible for developing and attaining the P&L, Bookings, Revenue and EBIDTA targets of its Cloud Solution lines. Before Optum, Mr. Green worked nearly six years, from March 2017 to May 2023, with Change Health Care, most recently as Vice President Cloud Solutions from March 2021 to May 2023. Previously, Mr. Green worked for more than 15 years with McKesson growing to Division Vice President, Sales where he led an organization of 50+ executives, salespersons and staff, across the US, Canada, and the US government territories. He holds a Bachelor of Science in Biochemistry from the University of Victoria, British Columbia, a Systems Analyst Diploma from Royal Roads University, British Columbia, and an Executive MBA from the Wharton School. We believe Mr. Green is well-qualified to serve as a member of our Board of Directors due to his experience as a public company executive and healthcare IT leader.

**Dr. Thomas Kosasa** is a renowned Ob/Gyn/Fertility specialist at the Pacific In Vitro Fertilization Institute and serves on the Board of Trustees of Pan Pacific Surgical and as a professor of reproductive endocrinology at the University of Hawaii, John A. Burns School of Medicine. Dr. Kosasa is a consultant for Maternal and Reproductive Health for the Food and Drug Administration and a past member for the Hawaii State Board of Medical Examiners and the Food and Drug Administration. Dr. Kosasa is a retired Major in the United States Army and was the Chief of Gyn-Surgical Service and the Director of the Infertility Division at Martin Army Hospital in Fort Benning, Georgia. Dr. Kosasa graduated from Dartmouth College and earned his medical degree at the McGill University School of Medicine. He completed his residency in obstetrics and gynecology and fellowship in reproductive endocrinology at Harvard Medical School in the Boston Hospital for Women and completed a Reproductive Endocrinology Fellowship at the Peter Bent Brigham Hospital, Harvard Medical School. Dr. Kosasa's professional societies include American College of Obstetricians and Gynecologists, American Fertility Society, Board of Trustees, Pan Pacific Surgical Association, Hawaii Medical Association and Pacific Coast Obstetrical and Gynecological Society. We believe Dr. Kosasa is well-qualified to serve as a member of our Board of Directors due to his extensive experience in the medical field.

**Dr. Kenneth Alleyne** is a board-certified orthopedic surgeon specializing in sports medicine, practicing in both Connecticut and Manhattan since 2004, where he serves as an attending surgeon at multiple hospital systems and has held faculty positions both domestically and internationally. Since 2007, Dr. Alleyne has served as the managing partner of HartHaven Partners, a healthcare consulting firm that supports private equity and venture capital firms. He is also co-founded NextLevel Health Partners, a Medicaid-managed care organization in the Midwest, in 2013, and Zing Healthcare, a technology-driven Medicare Advantage health plan, in 2020. Recognizing the challenges of population health and social determinants of health, in 2022, he also co-founded and served as CEO of Fizio Health, an AI-powered computer vision technology for remote physical therapy. Additionally, he serves as a team physician and consultant for various local, national, and international athletic organizations.

Committed to community service, Dr. Alleyne is the former chair of the Connecticut Health Foundation and currently sits on the boards of the University of Connecticut Health Center, the Louis Armstrong Educational Foundation in New York, and Student Achievement Through Opportunity, an organization dedicated to providing academic and arts enrichment for low-income students. Since 2019, he has also served on the board of Connecticut Public Television and Radio. Dr. Alleyne is a graduate of Williams College and completed his medical training at Wake Forest University. He pursued his residency at Howard University Hospital and later completed a fellowship in sports medicine, knee and shoulder surgery at Yale University, as well as a fellowship in tissue engineering at the Harvard-MIT Division of Health Sciences and Technology. We believe Dr. Alleyne is well-qualified to serve as a member of our Board of Directors due to his background and experience in healthcare and healthcare IT, particularly in industry startups.

**Sherry Coonse McCraw** has 30 years of leadership experience in engineering, finance, project management, and manufacturing at BMW Manufacturing Co., LLC ("BMW"). Ms. McCraw has served as a Senior Manager responsible as Chief Financial Officer, Vice President of Assembly Manufacturing, and currently holds the role of Vice President of Human Resources. Ms. McCraw began her career with BMW in 1993 with responsibilities for the facility's Testing and Finish operation. Over the next eight years, she played a key role in various aspects of assembly production, planning, engineering, and technology steering. In 2001, Ms. McCraw served as the project manager in Munich, Germany to manage the structural planning for the second-generation BMW X5. In 2004, she returned to Spartanburg, South Carolina as the Planning Manager of Assembly and Technology Steering. In 2007, Ms. McCraw managed the plant's 1.2 million square foot expansion of its second assembly hall in preparation to produce the BMW X3. In 2011, she was selected to lead BMW's largest single investment of $900 million to expand the plant for the fifth time in BMW's history. In 2013, Ms. McCraw was named Chief Financial Officer and Vice President Finance of BMW. From March 2018 to April 2022, she was appointed to lead both production halls in her role as Vice President of Assembly Manufacturing. Since April 2022, Ms. McCraw has served as the Vice President of Human Resources at BMW. Ms. McCraw currently serves on the Board of Directors for the North Carolina Textile Foundation. She has a Bachelor of Science in Textile Engineering from North Carolina State University. We believe Ms. McCraw is well-qualified to serve as a member of our Board of Directors due to her senior leadership experience in financial roles at a large company.

**Dr. Jeffrey Yu** serves as the Chief Medical Officer, Vice President and Chairman of the Board of Directors of OneMedNet, roles he has held since 2023. The concept of what would become Legacy OneMedNet was founded in 2015 by Dr. Yu, who applies his 28 years of sophisticated healthcare IT experience to the Company every day. Dr. Yu is a board-certified Radiologist and is also fellowship-trained and board-certified in Nuclear Medicine. In 2006, he was part of a small group that recognized there was a need to develop electronic sharing technology to help imaging specialists move patient imaging studies quickly, securely, and cost-effectively. Dr. Yu's early research and development led to the BEAM solution which helped improve care and outcomes for stroke and trauma patients. In 2015, he started the concept of what would become Legacy ONMD to commercialize the BEAM product. Since that time, Dr. Yu has remained an integral part of the strategic decision-making within OneMedNet. Dr. Yu received his B.S. at U.C. Berkeley and his M.D. at Wake Forest University, conducted MRI research at Stanford University, and completed his Radiology residency and Nuclear Medicine fellowship at the Mallinckrodt Institute at Washington University. We believe Dr. Yu is well-qualified to serve as a member of our Board of Directors due to his extensive healthcare IT experience.

**<u>Director Not Standing for Re-Election</u>**

**Jair Clarke**, age 44, has served on our Board Since October 2024. Jair is the Chairman's Executive Advisor and board advisor of World Wide Technology ($20B company) and the CEO/Chief AI Officer of Laigic, an A.I. and tech advisory firm of C-level Fortune 15 consultants and physicians, where he has served since November 2023. From August 2020 until July 2023, Mr. Clarke served as the Global Chief Technology Officer of Commercial Systems at Microsoft Corporation, where he was responsible for commercial systems, artificial intelligence, and products across all industries for Customers and Partner Solutions. Within this organization, Mr. Clarke was responsible for all technology and processes at scale to empower customers, partners, sellers.

From 2014 through 2020, Mr. Clarke was responsible for Disney's big data, digital analytics, and strategy technologies supporting the Chief Commercial Officer to influence traditional/non-traditional monetization, products, and experiences such as mobile apps, wearable devices, and e-commerce. Mr. Clarke was a leader for IBM's Watson, held a U.S. Top Secret SCI Full Scope Polygraph security clearance, oversaw all technical capabilities for the United States counter-narcotics command partnering with various government agencies (e.g. CIA, FBI), increased business revenue by 800% within 2 years, and consistently doubled annual revenue. He's had global P&L responsibility and held roles as the executive champion of diversity and inclusion. From 2007 to 2014, Mr. Clarke was an IT & Business Development Executive at IBM. From 2005 to 2007, Mr. Clarke consistently expanded his technology responsibilities at Lockheed Martin. Jair has served as a member of the board of directors of the publicly traded company Xponential Fitness (NYSE: XPOF) since July 2022. Mr. Clarke holds a B.B.A. degree in computer information systems from the University of Miami. We believe Mr. Clarke is well-qualified to serve as a member of our Board of Directors due to his experience in technology, business and operations roles concentrated in product management, digital transformation, digital marketing, cybersecurity, data science, emerging technology, business architecture, customer experiences and worldwide innovation.

**OUR BOARD RECOMMENDS A VOTE "FOR" EACH CLASS II DIRECTOR NOMINEE.**

**PROPOSAL 2 – RATIFICATION OF THE APPOINTMENT OF WITHUMSMITH+BROWN, PC AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The Audit Committee of our Board has appointed Withum to serve as our independent registered public accounting firm for the year ending December 31, 2025. Withum has served as our independent registered public accounting firm since June 2024.

Our Board is asking stockholders to ratify the selection of Withum as our independent registered public accounting firm. Stockholder approval or ratification is not required to appoint Withum; however, our Board believes that submitting the appointment of Withum to stockholders for ratification is good corporate governance. If stockholders do not ratify this appointment, the Audit Committee will investigate the reasons for stockholder rejection and will re-consider the appointment of Withum. Even if the selection of Withum is ratified, the Audit Committee, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that a change would be in the best interest of the Company and our stockholders.

A representative of Withum is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions.

**Prior Audit Firm**

On May 3, 2024, the SEC permanently suspended BF Borgers CPA PC ("BF Borgers") from appearing or practicing before the SEC as a registered public accounting firm. Following this order, on May 6, 2024, the Board approved the dismissal of BF Borgers as the Company's independent registered public accounting firm. On June 3, 2024, the Company appointed Withum as the Company's independent registered public accounting firm.

The report of BF Borgers on the Company's financial statements for the fiscal year ended December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles other than an explanatory paragraph relating to the Company's ability to continue as a going concern.

During the fiscal year ended December 31, 2023, and through the date of dismissal on May 6, 2024, there were no "disagreements" with BF Borgers on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of BF Borgers would have caused BF Borgers to make reference thereto in its reports on the financial statements for such years. During the fiscal year ended December 31, 2023, and through May 6, 2024, there were no "reportable events" (as defined in Item 304(a)(1)(iv) and Item 304(a)(1)(v) of Regulation S-K), except for the identified material weaknesses in the Company's internal control over financial reporting as disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023.

**Fees Paid to Independent Registered Public Accounting Firm**

Fees billed by Withum and BF Borgers for services provided during the years ended December 31, 2024 and 2023 were as follows:

***Withum***

---

| | | |
|:---|:---|:---|
|  | **Year Ended** | **Year Ended** |
|  | **December 31, 2023** | **December 31, 2024** |
| Audit Fees |  | $790000 |
| Audit-Related Fees |  |  |
| Tax Fees |  | 50000 |
| All Other Fees |  |  |
| Total |  | $840000 |

---

***BF Borgers***

---

| | | |
|:---|:---|:---|
|  | **Year Ended** | **Year Ended** |
|  | **December 31, 2023** | **December 31, 2024** |
| Audit Fees | $203500 |  |
| Audit-Related Fees |  |  |
| Tax Fees | 15000 |  |
| All Other Fees |  |  |
| Total | $218500 |  |

---

Audit fees include fees associated with (i) the annual audit of our consolidated financial statements and internal control over financial reporting, (ii) the review of our periodic reports, (iii) accounting consultations, (iv) services related to, or required by, statute or regulation, such as consents, and (v) other audit services related to SEC and other regulatory filings. Tax fees represent fees for tax consulting services. Fees paid to Withum in 2024 includes (i) audit fees of $375,000 for the re-audit of the consolidated annual financial statements for the year ended December 31, 2023 and review of the amended annual report related thereto and other periodic reports, and (ii) tax fees of $25,000 related to 2023 tax periods.

All of the services and fees of BF Borgers and Withum reflected in the above table were pre-approved by the Audit Committee pursuant to the pre-approval policy and procedures set forth below.

**Audit Committee Pre-Approval Policy and Procedures**

Under its charter, the Audit Committee is responsible for approving the fees and any other significant compensation paid to our independent accountants and pre-approving any non-audit services to be performed by our independent accountants. The pre-approval requirement may be waived only if the non-audit services meet a de minimis exception allowed by law. In carrying out this responsibility, the Audit Committee follows the following general procedures for the preapproval of non-audit services:

● Each year the Audit Committee reviews and pre-approves a schedule of the proposed non-audit services and estimated fees to be provided by the independent accountants during the next annual audit cycle.

● Actual amounts paid to the independent accountants are monitored by management and reported to the Audit Committee.

● Any non-audit services proposed to be provided by the independent accountants and the related fees that have not been pre-approved during the annual review by the Audit Committee must be pre-approved by the Audit Committee in advance of any work performed (unless the services meet the de minimis exception allowed by law).Incremental fees for previously approved non-audit services that are expected to exceed the previously approved fee estimate must also be pre-approved by the Audit Committee.

**OUR BOARD RECOMMENDS A VOTE "FOR" THE RATIFICATION OF THE APPOINTMENT OF WITHUMSMITH+BROWN, PC AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.**

**Audit Committee Report**

The Audit Committee is appointed by the Board to assist the Board in fulfilling its oversight responsibilities with respect to (a) the integrity of OneMedNet's financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory requirements, (b) the qualifications, independence, and performance of OneMedNet's independent registered public accounting firm, (c) the performance of OneMedNet's internal audit function, and (d) other matters as set forth in the charter of the Audit Committee approved by the Board.

Management is responsible for OneMedNet's financial statements and the financial reporting process, including the systems of internal controls and disclosure controls and procedures. Withum, as OneMedNet's independent registered public accounting firm, is responsible for performing an independent audit of OneMedNet's financial statements in accordance with generally accepted auditing standards and OneMedNet's internal control over financial reporting and for issuing a report thereon. The Audit Committee's responsibility is to monitor and oversee these processes.

In connection with these responsibilities, the Audit Committee reviewed and discussed with management and Withum the audited consolidated financial statements of OneMedNet for the year ended December 31, 2024. The Audit Committee also discussed with Withum the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board ("PCAOB") and the SEC. In addition, the Audit Committee received the written disclosures and the letter from Withum required by the applicable requirements of the PCAOB regarding Withum's communications with the Audit Committee concerning independence and has discussed with Withum its independence.

Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board that the audited consolidated financial statements of OneMedNet be included in OneMedNet's Annual Report on Form 10-K for the year ended December 31, 2024, that was filed with the SEC on April 15, 2025.

The Audit Committee

Dr. Kenneth Alleyne (Chair)

Sherry Coonse McCraw

Jair Clarke

Dr. Thomas Kosasa

**Corporate Governance**

**Director Independence**

The rules of The Nasdaq Stock Market LLC ("Nasdaq") require that a majority of the Company's board of directors be independent. An "independent director" is generally defined under applicable Nasdaq rules as a person other than an officer or employee of the Company or its subsidiaries or any other individual having a relationship which, in the opinion of the Board, would interfere with the director's exercise of independent judgment in carrying out the responsibilities of a director.

Our Board is comprised of a majority of independent directors. Our Board has determined that each of Dr. Alleyne, Eric Casaburi, Jair Clarke, Sherry Coonse McCraw, Dr. Thomas Kosasa, and Andrew Zeinfeld is an independent director under the rules of the SEC and Nasdaq and do not have any material relationship with us other than their positions as directors and stockholders. In making these determinations, our Board considered past employment, remuneration, and all other relationships each of these directors have with OneMedNet, as well as the specific independence tests set forth in Nasdaq's director independence rules. As our President and Chief Executive Officer, our Chief Financial Officer and Corporate Secretary, and our Chief Medical Officer and Vice President, respectively, none of Mr. Green, Mr. Golden, or Dr. Yu is considered an independent director under SEC and Nasdaq rules due to their current employment with the Company.

**Board Leadership Structure and Role in Risk Management**

Our Board has responsibility for establishing broad corporate policies and reviewing our overall performance rather than day-to-day operations. The primary responsibility of our Board is to oversee our management and, in doing so, serve our best interests and the best interests of our stockholders. Our Board selects, evaluates and provides for the succession of executive officers and, subject to stockholder election, directors. It reviews and approves corporate objectives and strategies, and evaluates significant policies and proposed major commitments of corporate resources. Our Board also participates in decisions that have a potential major economic impact on us. Management keeps the directors informed of Company activity through regular communication, including written reports and presentations at Board and committee meetings.

Our corporate governance practices do not indicate a particular board structure, and our Board has the flexibility to select its chair and our chief executive officer in the manner that it believes is in the best interests of our stockholders. Accordingly, the positions of Chair and the Chief Executive Officer may be filled by either one individual or two individuals. The Board has elected to separate the positions of Chair and Chief Executive Officer.

Our Board believes that our current leadership structure and the composition of our Board protect stockholder interests and provide adequate independent oversight, while also providing outstanding leadership and direction for our Board and management. Aside from our President and Chief Executive Officer, our Chief Financial Officer and Corporate Secretary, and our Chaiman and Chief Medical Officer, each of our other directors is "independent" under Nasdaq standards, as more fully described herein. The independent directors meet in executive sessions, without management present, during each regularly scheduled Board meeting and are very active in the oversight of our Company. In addition, our Board and each committee of Board has complete and open access to any member of management and the authority to retain independent legal, financial and other advisors as they deem appropriate.

Effective risk oversight is an important priority of the Board. Because risks are considered in virtually every business decision, the Board discusses risk throughout the year generally or in connection with specific proposed actions. The Board's approach to risk oversight includes understanding the critical risks in our business and strategy, evaluating our risk management processes, allocating responsibilities for risk oversight among the full Board, and fostering an appropriate culture of integrity and compliance with legal responsibilities.

Our Board has an active role, as a whole and at committee levels, in overseeing management of our risks. Our Board oversees management of risks associated with operations and cybersecurity. The Board of Directors and management are actively involved in reviewing our information security and cybersecurity strategies and updating these strategies as risks evolve. While each standing Board committee is responsible for overseeing the management of risks relating to its area of oversight, the entire Board is regularly informed about these risks through committee meeting attendance or committee reports.

The Audit Committee of the Board of Directors has oversight of our cybersecurity program and is responsible for reviewing and assessing the Company's cybersecurity and data protection policies, procedures and resource commitment, including key risk areas and mitigation strategies. As part of this process, the Audit Committee receives regular updates from the Chief Technology Officer on critical issues related to our information security risks, cybersecurity strategy, supplier risk and business continuity capabilities. The Audit Committee also oversees the management of accounting, financial reporting, and financial risks and the management of our compliance program. Additionally, the Audit Committee oversees our procedures for the receipt, retention, and treatment of complaints received by us regarding accounting, internal accounting controls, or audit matters. The Compensation Committee is responsible for overseeing the management of risks relating to our compensation plans and arrangements. The Nominating and Corporate Governance Committee manages risks associated with director independence and potential conflicts of interest.

**Communication with Directors**

Stockholders and other interested parties who wish to communicate with our Board, including our independent or non-management directors as a group, or any other individual director, may do so by submitting a written communication to our Corporate Secretary at the following address:

OneMedNet Corporation<br> Attention: Corporate Secretary<br> 6385 Old Shady Oak Road, Suite 250<br> Eden Prairie, Minnesota 55344

Our Corporate Secretary, in consultation with appropriate members of our Board, as necessary, will review all incoming communications and, if appropriate, all such communications will be forwarded to the appropriate member or members of our Board. Our Corporate Secretary may discuss these communications with our legal counsel, independent advisors, non-management directors, or management and may take other action or no action as he or she determines in good faith, using reasonable judgment and discretion.

**Hedging and Pledging Transactions**

Our directors and executives are subject to various trading restrictions under our Insider Trading Policy. These individuals are prohibited from entering into transactions involving our securities during quarterly blackout periods and certain other special blackout periods and must receive our permission before entering into these transactions. The Company's Insider Trading Policy also prohibits executive officers and directors from engaging in any transaction in which they may profit from short-term speculative swings in the value of the Company's securities, unless such executive officers and directors received advance approval to engage in such a transaction. This includes "short sales" (selling borrowed securities that the seller hopes can be purchased at a lower price in the future) or "short sales against the box" (selling owned, but not delivered securities), and "put" and "call" options. Our Insider Trading Policy provides that no employee, officer or director may acquire, sell or trade in any interest or position relating to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale "against the box"), or engage in hedging transactions (including "cashless collars").

**Clawback Policy**

In November 2024, the Board of Directors adopted a compensation clawback policy (the "Clawback Policy"). The Clawback Policy requires the Company to clawback erroneously awarded incentive compensation received by current and former executive officers during the three fiscal years that precede the date the Company is required to prepare an accounting restatement due to material noncompliance with a financial reporting requirement. The Clawback Policy also allows the Company to clawback compensation from any employee who is determined to have engaged in a misconduct event.

**Committees and Meetings**

During the fiscal year ended December 31, 2024, our Board held two meetings. No director attended fewer than 75% of the total number of meetings of our Board and of committees of our Board on which he or she served during fiscal 2024. Our Board has adopted a policy under which each member of our Board makes every effort, but is not required, to attend each annual meeting of our stockholders. Four of our Board members then serving attended the 2024 annual meeting of stockholders.

Our Board has three standing committees: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. Each of these standing committees is comprised solely of independent directors. As necessary, each of these committees meets in executive session without management present. The charters for these committees are available on our website at https://www.onemednet.com/. Links to websites included in this Proxy Statement are provided solely for convenience purposes. Content on the websites, including content on our Company website, is not, and shall not be deemed to be, part of this Proxy Statement or incorporated herein or into any of our other filings with the SEC.

In December 2024, the Board established the Commercial Committee to assist our Chief Executive Officer and other members of Company management to identify, pursue, and close high-value enterprise sales deals, as well as provide oversight and guidance to management in connection with significant commercial transactions for the Company. The initial members of the Commercial Committee were Jair Clarke and Andrew Zeinfeld. The Commercial Committee did not hold any meetings in 2024.

The following table sets forth the current chairperson and members of each standing committee of the Board and the number of meetings each such committee held in 2024.

---

| | | | |
|:---|:---|:---|:---|
| **Name of Director** | **Audit** <br> **Committee** | **Compensation** <br> **Committee** | **Nominating<br> and Corporate<br> Governance<br> Committee** |
| Dr. Kenneth Alleyne | Chair |  |  |
| Eric Casaburi |  |  | Chair |
| Jair Clarke\*\* | X | X |  |
| Sherry Coonse McCraw | X |  |  |
| Dr. Thomas Kosasa | X |  |  |
| Andrew Zeinfeld |  | Chair | X |
| **Number of Meetings in 2024** | 4 | 1 | 2 |

---

*\*\* Not standing for re-election at the Annual Meeting.*

**Audit Committee**

The Audit Committee (a) assists the Board in fulfilling its oversight of: (i) the quality and integrity of the Company's financial statements; (ii) the Company's compliance with legal and regulatory requirements relating to the Company's financial statements and related disclosures; (iii) the qualifications and independence of the Company's independent auditors; and (iv) the performance of the Company's independent auditors and the Company's internal audit function; and (b) prepares any reports that the rules of the SEC required be included in the Company's annual proxy statement. The Audit Committee also reviews and approves all related party transactions, as described in more detail elsewhere in this proxy statement.

The Audit Committee is responsible for the oversight of the Company's financial reporting process on behalf of the Board and such other matters as specified in the Audit Committee's charter or as directed by the Board. Our Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the work of any registered public accounting firm engaged by us for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for us (or to nominate the independent registered public accounting firm for stockholder approval), and each such registered public accounting firm must report directly to the Audit Committee. Our Audit Committee must approve in advance all audit, review and attest services and all non-audit services (including, in each case, the engagement and terms thereof) to be performed by our independent auditors, in accordance with applicable laws, rules and regulations.

Our Board has determined that each member of the Audit Committee is financially literate in accordance with the rules of Nasdaq and is independent under Nasdaq's director independence standards and applicable SEC rules. In addition, the Board has determined that Ms. Coonse McCraw qualifies as an "audit committee financial expert" as defined by SEC rules.

**Compensation Committee**

The Compensation Committee (i) assists the Board in discharging its responsibilities with respect to compensation of the Company's executive officers and directors, (ii) evaluates the performance of the executive officers of the Company, and (iii) administers the Company's stock and incentive compensation plans and recommends changes in such plans to the Board as needed. Our Board has determined that each member of the Compensation Committee is independent under Nasdaq's director independence standards and applicable SEC rules. Among other things, our Compensation Committee is responsible for:

● evaluating the performance of our Chief Executive Officer;

● evaluating the performance of our other executive officers (including officers reporting under Section 16 of the Exchange Act);

● reviewing and approving our overall compensation philosophy, programs, policies, and practices;

● administering our Clawback Policy; and

● reviewing and developing short- and long-term management succession plans.

The Compensation Committee may form and delegate responsibility to subcommittees as it deems necessary or appropriate, provided that any subcommittee must meet all applicable independence requirements.

**Nominating and Corporate Governance Committee**

The Nominating and Corporate Governance Committee assists the Board in (i) identifying qualified individuals to become directors, (ii) determining the composition of the Board and its committees, (iii) developing succession plans for executive officers, (iv) monitoring a process to assess Board effectiveness, and (v) developing and implementing the Company's corporate governance procedures and policies. Our Board has determined that each member of the Nominating and Corporate Governance Committee is independent under Nasdaq's director independence standards and applicable SEC rules.

The Nominating and Corporate Governance Committee considers candidates recommended by stockholders as well as from other sources such as other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating and Corporate Governance Committee will evaluate a candidate's qualifications in accordance with its written charter and, if the Nominating and Corporate Governance Committee believes a candidate would be a valuable addition to the Board, it recommends his or her candidacy to the full Board. The Nominating and Corporate Governance Committee does not alter its criteria for evaluating candidates, including the criteria described above, for stockholder recommended candidates. Threshold criteria include personal integrity and sound judgment, business and professional skills and experience, independence, knowledge of our industry, conflicts of interest, the extent to which the candidate would fill a present need on our board of directors, and concern for the long-term interests of our stockholders. Our Nominating and Corporate Governance Committee has not adopted a formal diversity policy in connection with the consideration of director nominations or the selection of nominees. However, the Nominating and Corporate Governance Committee will consider issues of diversity among its members in identifying and considering nominees for director and strive where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, ethnicity and country of citizenship on our board of directors and its committees.

Stockholders may recommend individuals to the Nominating and Corporate Governance Committee for consideration as director candidates by submitting the names of such individuals, together with appropriate biographical information and background materials to the Corporate Secretary, OneMetNed Corporation, 6385 Old Shady Oak Road, Suite 250, Eden Prairie, Minnesota 55344. Stockholders also have the right under our Bylaws to nominate director candidates directly, without any action or recommendation on the part of the Nominating and Corporate Governance Committee or the Board. Pursuant to our Bylaws, nominations of persons for election to the Board at an annual meeting or at any special meeting of stockholders for the purpose of electing directors may be made by or at the direction of the Board or by any stockholder of record entitled to vote for the election of directors at the meeting who complies with the following notice procedures. Such nominations, other than those made by, or at the direction of, or under the authority of the Board, shall be made pursuant to timely notice in writing to the Secretary of the Company by a stockholder of record at such time. To be timely, a stockholder's notice must be received at the principal executive offices of the Company (a) in the case of an annual meeting, not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day before the anniversary date of the immediately preceding annual meeting; provided, however, that if the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder in order to be timely must be so received not earlier than the opening of business on the 120th day before the meeting and not later than the later of the close of business on the 90th day before the meeting or the close of business on the tenth day following the day on which public announcement of the date of the annual meeting was first made by the Company; and (b) in the case of a special meeting of stockholders called for the purpose of electing directors, not later than the close of business on the 10th day following the day on which public announcement of the date of the special meeting is first made by the Company. Such stockholder's notice to the Corporate Secretary must set forth (a) as to each person whom the stockholder proposes to nominate for election or re-election as a director, (i) the name, age, business address and residence address of the person, (ii) the principal occupation or employment of the person, (iii) the class or series and number of shares of capital stock of the Company that are owned beneficially or of record by the person and (iv) any other information relating to the person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder; and (b) as to the stockholder giving the notice (i) the name and record address of the stockholder as they appear on the Company's books and the name and address of the beneficial owner, if any, on whose behalf the nomination is made, (ii) the class or series and number of shares of capital stock of the Company that are owned beneficially and of record by such stockholder and the beneficial owner, if any, on whose behalf the nomination is made, (iii) a description of all arrangements or understandings relating to the nomination to be made by such stockholder among such stockholder, the beneficial owner, if any, on whose behalf the nomination is made, each proposed nominee and any other person or persons (including their names), (iv) a representation that such stockholder (or a qualified representative of such stockholder) intends to appear in person or by proxy at the meeting to nominate the persons named in its notice, and (v) any other information relating to such stockholder and the beneficial owner, if any, on whose behalf the nomination is made that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder. Such notice must be accompanied by a written consent of each proposed nominee to being named as a nominee and to serve as a director if elected.

The Board or the chairman of the meeting may, if the facts warrant, determine and declare that a nomination was not made in accordance with the foregoing procedures, and the defective nomination will be disregarded. If the stockholder (or a qualified representative of the stockholder) does not appear at the meeting to present the nomination, such nomination will be disregarded, notwithstanding that proxies in respect of such nomination may have been received by the Company.

**Governance-Related Materials**

You can find copies of our governance-related materials, including our Code of Ethics and Business Conduct, our Insider Trading Policy, and the charters of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee in the "Investor Relations" section of our website at https://www.onemednet.com/. Copies of these materials also are available in print to any stockholder who requests them by sending a written request to the following address:

Corporate Secretary<br> OneMedNet Corporation<br> 6385 Old Shady Oak Road, Suite 250<br> Eden Prairie, Minnesota 55344

**EXECUTIVE OFFICERS**

The following table sets forth certain information about our executive officers, as of November 7, 2025:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Title/Position** |
| Aaron Green | 52 | Chief Executive Officer, President and Director |
| Robert Golden | 63 | Interim Chief Financial Officer, Corporate Secretary and Director |
| Dr. Jeffrey Yu | 57 | Founder, Chief Medical Officer, Vice President, Chairman of the Board of Directors |

---

Biographical information for Mr. Green, Mr. Golden and Dr. Yu is provided above in this proxy statement as part of Proposal 1—Election of Class II Directors.

**Executive Compensation**

**2024 Summary Compensation Table**

The following table sets forth the total compensation earned for services rendered during the years indicated by our named executive officers as of December 31, 2024.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and principal position** | **Year** | **Salary**<br> **($)** | **Bonus**<br> **($)** | **Stock awards**<br> **($)<sup>(1)</sup>** | **Option awards**<br> **($)<sup>(1)</sup>** | **All other compensation**<br> **($)** | **Total**<br> **($)** |
| Aaron Green<sup>(2)</sup> | 2024 | 350000 |  | 258000 |  |  | 608000 |
| *President and Chief Executive Officer* | 2023 | 213512 | 106435 |  |  |  | 319947 |
| *Robert Golden<sup>(3)</sup><br> *Chief Financial Officer**  | 2024 |  |  | 103000 |  | 48000<sup>(3)</sup> | 151000 |
| *Dr. Jeffrey Yu<sup>(4)</sup>*<br> *Founder, Chief Medical Officer, Vice President, Chairman of the Board of Directors* | 2024 | 300000<sup>(4)</sup> |  | 19350 |  |  | 319350 |
| Paul Casey<sup>(3)</sup> | 2024 | 34892 |  | 19350 | 34218 | 12000 | 100460 |
| *Former Chief Executive Officer* | 2023 | 144000 |  | 180250 |  |  | 324250 |
| Lisa Embree<sup>(6)</sup> | 2024 | 170000 |  | 111800 |  |  | 281800 |
| *Former Chief Financial Officer* | 2023 | 225000 | 50000 |  |  |  | 275000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Award
 amounts reflect the aggregate grant date fair value with respect to awards granted, as determined
 pursuant to Financial Accounting Standards Board ("FASB") ASC Topic 718. The
 assumptions used to calculate the aggregate grant date fair value of option awards are set
 forth in Note 11 to the consolidated financial statements included in Item 8 of our Annual
 Report on Form 10-K for the year ended December 31, 2024. These amounts do not necessarily
 reflect actual compensation earned or to be earned by our named executive officers.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Mr.
 Green has served as President since May 2023 and as Chief Executive Officer since March 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Mr.
 Golden was appointed to serve as Chief Financial Officer on an interim basis on August 30,
 2024 and was appointed on a permanent basis on January 1, 2025. Amount in "All Other
 Compensation" represents cash paid under Mr. Golden's consulting agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Dr.
 Yu was not a named executive officer in 2023. On October 1, 2024, Dr. Yu received
 a grant of 230,769 restricted stock units ("RSUs") in lieu of $132,216 of his
 annual salary, with the RSUs vesting on July 1, 2025, subject to Dr. Yu's continuous
 service with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Mr.
 Casey retired in March 2024. Amount in "All Other Compensation" represents severance
 payment in connection with Mr. Casey's Resignation Agreement and Release as described
 in further detail below.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Ms.
 Embree served as a consultant from January 2022 through April 15, 2022, and then as Chief
 Financial Officer until her resignation in August 2024.

**Narrative Disclosure to Summary Compensation Table**

The compensation of the Company's named executive officers is comprised of the following major elements: (a) base salary, (b) bonuses, and (c) long-term equity incentives, consisting primarily of restricted stock units granted under the Company's 2022 Equity Incentive Plan. These principal elements of compensation are described below.

*Base Salary*

Base salary is provided as a fixed source of compensation for our named executive officers. Adjustments to base salaries are reviewed annually by the Compensation Committee and may be adjusted from time to time to reflect promotions or other changes in the scope of breadth of the named executive officer's role or responsibilities, as well as to maintain market competitiveness.

For 2024, the annual base salaries of Mr. Green, Mr. Golden and Dr. Yu were $350,000, $144,000 and $300,000, respectively. See "Executive Employment Arrangements" below for additional information. On October 1, 2024, Dr. Yu received a grant of 230,769 restricted stock units ("RSUs") in lieu of $132,216 of his annual base salary, with the RSUs vesting on July 1, 2025, subject to Dr. Yu's continuous service with the Company.

*Cash Bonuses*

 

Annual cash bonuses may be awarded based on qualitative and quantitative performance standards to reward performance of our named executive officers. For 2024, no bonuses were approved for our named executive officers.

 

*Long-Term Equity Incentives*

Grants made under our 2022 Equity Incentive Plan (the "2022 Plan") provide continual motivation for our officers, employees, consultants and directors to achieve our business and financial objectives, align their interests with the long-term interests of our stockholders, and provide a long-term retention incentive.

For 2024, our named executive officers were award RSU awards with vesting terms set forth below, subject to continuous service with the Company through each applicable vesting date. See "Executive Employment Arrangements" below for additional information.

**Executive Employment Arrangements**

The Company previously entered into employment agreements with Aaron Green, Robert Golden and former executive officers, Paul Casey and Lisa Embree. The employment agreements provide for at-will employment that may be terminated by the Company with or without cause, by the executive with or without good reason, or mutually terminated by the parties. The Compensation Committee also approved certain employment compensation arrangements with Dr. Yu.

<u>Aaron Green</u>

The Company entered into an employment agreement with Mr. Green on May 7, 2023, with a start date of May 23, 2025, which provides for a $350,000 annual base salary, eligibility to receive an annual cash performance bonus of up to $175,000 upon achievement of certain performance goals, and eligibility to receive additional shares under the Company's equity plan, subject to approval and periodic review by the Company. In the event that his employment is terminated by the Company without Cause (as defined in the employment agreement), or is terminated by Mr. Green for Good Reason (as defined in the employment agreement), subject to execution of a standard release, after the date of his termination of employment (the "Termination Date") he will be entitled to the following severance payment, as follows: (a) if the Termination Date is after six (6) months' of employment, but before he has completed 12 months' of employment, he will receive three months' salary; and (b) if the Termination Date is after 12 months' employment he will receive six months' salary.

On January 20, 2024, Mr. Green was awarded 600,000 RSUs, with 1/3 of the RSUs vesting on the first anniversary of the vesting start date and the remaining RSUs vesting in equal monthly installments over the 24 months following first anniversary of the vesting start. The vesting start date for these RSUs granted to Mr. Green was May 23, 2023.

<u>Robert Golden</u>

 

The Company entered into a consulting agreement, effective August 30, 2024, with Mr. Golden in connection with his service as interim chief financial officer ("CFO"), prior to his permanent appointment in January 2025. The consulting agreement provided for a monthly fee of $12,000 and an initial grant of 100,000 RSUs that will fully vest on the first anniversary thereafter, subject to Mr. Golden's continuous service with the Company.

On January 31, 2025, the Company appointed Mr. Golden as CFO of the Company on a permanent basis, and in connection with his permanent appointment as CFO, in addition the continued compensation in the employment agreement, the Company agreed that Mr. Golden will also receive a cash bonus of $25,000 and a grant of RSUs equal to $25,000, which will be fully vested on the grant date.

<u>Dr. Jeffrey Yu</u>

The Company previously agreed with Dr. Yu of a base salary of $300,000 for his service to the Company. On October 1, 2024, the Compensation Committee of the Board reaffirmed a $300,000 base salary for Dr. Yu, and granted Dr. Yu 230,769 RSUs in lieu of $132,216 of his annual base salary for 2024. These RSUs vest on July 1, 2025, subject to Dr. Yu's continuous service with the Company.

<u>Former Executive Officers</u>

 

The Company entered into an employment agreement, dated March 28, 2022, with Mr. Casey, which provided for a $144,000 annual salary, eligibility to receive 147,000 shares of stock upon the successful fundraising of an amount equal to or greater than $5,000,000, and further equity subject to the approval of the Board of Directors. On March 22, 2024, Mr. Casey notified the Company of his intention to retire as Chief Executive Officer of the Company effective March 29, 2024. Effective October 1, 2024, Mr. Casey resigned from the Board of Directors and the Compensation Committee of the Board of Directors. In connection with Mr. Casey's retirement, Mr. Casey and the Company entered into a Resignation Agreement and Release, dated March 22, 2024, pursuant to which Mr. Casey was paid $12,000 as a severance payment, and the Board approved a stock option grant providing for the grant of a stock option to purchase 147,000 shares of common stock that vested immediately on the date of board approval.

 

The employment agreement for Ms. Embree provided for a $225,000 annual base salary, eligibility to receive an annual cash performance bonus of twenty-five percent (25%) of her annual salary upon her achievement of certain performance goals, and eligibility to receive additional shares under the Company's equity plan, subject to approval by the Board of Directors. In connection with her separation from the Company, Ms. Embree received one month's salary, the continuation of all her benefits for one month, and the ability to vest one-third of her prior equity awards (such portion equal to 86,667 shares) on the one-year anniversary of the grant date.

**2024 Outstanding Equity Awards at Fiscal Year-End**

The following table summarizes information regarding equity-based awards held by our named executive officers as of December 31, 2024.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** |
| <br>**Name** |<br>**Grant Date** | **Number of Securities Underlying Unexercised Options—Exercisable (#)** | **Number of Securities Underlying Unexercised Options—Unexercisable (#)** | **Option Exercise Price ($)** | **Option Expiration Date** | **Number of shares or units of stock that have not vested (#)** | **Market value of shares of units of stock that have not vested ($)<sup>(1)</sup>** |
| Aaron Green | 1/19/2024 |  |  |  |  | 283333<sup>(2)</sup> | 385333 |
| Robert Golden | 8/30/2024 |  |  |  |  | 100000<sup>(3)</sup> | 136000 |
| Dr. Jeffrey Yu | 10/1/2024 |  |  |  |  | 230769<sup>(4)</sup> | 313846 |
| Paul Casey<sup>(5)</sup> | 10/1/2024 | 147000 |  | 1.00 | 10/1/2029 |  |  |
| Lisa Embree<sup>(6)</sup> |  |  |  |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Based
 on the closing price of our common stock of $1.36 on December 31, 2024, the last trading
 day of our fiscal year 2024, as reported by Nasdaq.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Represents
 RSUs that vest with 1/3 of the RSUs vesting on the first anniversary of the vesting start
 date and the remaining RSUs vesting in equal monthly installments over the 24 months following
 first anniversary of the vesting start date.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Represents
 RSUs that vest in full on August 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Represents
 RSUs that vest in full on July 1, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Mr.
 Casey retired in March 2024 and continued to serve as a member of the Board until October
 1, 2024. Mr. Casey was granted 147,000 fully vested stock options upon his retirement and
 the 45,000 RSUs granted as compensation for 2024 Board service were accelerated in connection
 with his separation from the Board. The stock options were forfeited without exercise 90
 days after his termination of service with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Ms.
 Embree resigned in August 2024, and the Board accelerated the vesting of 86,667 RSUs, or
 1/3 of the 260,000 RSUs that were scheduled to cliff vest on January 1, 2025. Ms. Embree
 forfeited the remaining 173,333 unvested RSUs.

**Director Compensation**

In April 2024, the Board adopted a revised director compensation policy (the "Director Compensation Policy"). The Director Compensation Policy provides for the annual automatic grant of 45,000 RSUs to each director for each full year of service. The Company also reimburses all of its directors for all reasonable out-of-pocket expenses incurred in connection with attendance at meetings of the Board.

The following table sets forth information concerning compensation paid or earned for services rendered to us by the members of our Board of Directors for the fiscal year ended December 31, 2024. Compensation paid to Aaron Green, Robert Golden and Jeffrey Yu is included in the section entitled, "Executive Compensation" and excluded from the table below:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Fees Earned or Paid in Cash ($)** | **Stock<br> Awards<br> ($)<sup>(1)</sup>** | **Total<br> ($)** |
| Eric Casaburi | – | 19350 | 19350 |
| Jair Clarke | – | 6579 | 6579 |
| Sherry Coonse McCraw | – | 6579 | 6579 |
| Dr. Thomas Kosasa | – | 19350 | 19350 |
| Andrew Zeinfeld | – | 22438 | 22438 |
| Scott Holbrook<sup>(2)</sup> | – | 19350 | 19350 |
| Dr. Julianne (Sun Joo) Huh<sup>(3)</sup> | – | 19350 | 19350 |
| Paul Casey<sup>(4)</sup> | – | 19350 | 19350 |
| Erkan Akyuz<sup>(4)</sup> | – | 19350 | 19350 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Award
 amounts reflect the aggregate grant date fair value with respect to awards granted, as determined
 pursuant to FASB ASC Topic 718. The assumptions used to calculate the aggregate grant date
 fair value of option awards are set forth in Note 11 to the consolidated financial statements
 included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Mr.
 Holbrook retired from the Board effective March 29, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Dr.
 Huh resigned from the Board effective August 12, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Mr.
 Casey and Mr. Akyuz each resigned from the Board on October 1, 2024.

**Security Ownership of Certain Beneficial Owners and Management**

The table below sets forth certain information regarding the beneficial ownership of our Common Stock by beneficial owners of more than 5% of our outstanding Common Stock, each current director, each named executive officer included in the Summary Compensation Table, and all current directors and executive officers as a group, as of October 23, 2025 (unless otherwise noted below). Percentage ownership is based on 51,157,069 shares of Common Stock outstanding as of October 23, 2025.

We have determined beneficial ownership in accordance with the rules of the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares subject to options, restricted stock units ("RSUs"), or other rights, held by such person that are currently exercisable or convertible, or will become exercisable or convertible or will vest within 60 days of October 23, 2025, are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.

Unless otherwise indicated, the address of all listed stockholders is c/o OneMedNet Corporation, 6385 Old Shady Oak Road, Suite 250, Eden Prairie, Minnesota 55344. Except as indicated by the footnotes below, we believe that the persons and entities named in the table below have sole voting and investment power with respect to all securities that they beneficially own, subject to applicable community property laws.

---

| | | |
|:---|:---|:---|
| **Name** | **Number of Shares of Common Stock Beneficially Owned<br> (#)** | **Percent of Class<br> (%)** |
| **5% Owners** |  |  |
| James Sixsmith<sup>(1)</sup> | 4604955 | 9.0% |
| Data Knights LLC | 3415275 | 6.7% |
| Off the Chain, LP<sup>(2)</sup> | 3215650 | 6.3% |
| TD Securities (USA) LLC<sup>(3)</sup> | 2970100 | 5.8% |
| **Directors and Named Executive Officers** |  |  |
| Aaron Green<sup>(4)</sup> | 601381 | 1.2% |
| Robert Golden | 169572 | \* |
| Dr. Jeffrey Yu<sup>(5)</sup> | 7097987 | 13.8% |
| Dr. Kenneth Alleyne |  |  |
| Eric Casaburi | 65475 | \* |
| Jair Clarke | 11342 | \* |
| Sherry Coonse McCraw | 11342 | \* |
| Dr. Thomas Kosasa<sup>(6)</sup> | 15773725 | 30.8% |
| Andrew Zeinfeld | 254382 | \* |
| **All Current Directors and Executive Officers as a Group (9 people)** | 23985206 | 46.2% |
| **Former Executive Officers** |  |  |
| Paul Casey<sup>(7)</sup> |  |  |
| Lisa Embree<sup>(8)</sup> |  |  |

---

\* Represents beneficial ownership of less than 1%.

&nbsp;&nbsp;&nbsp;&nbsp;(1) Excludes
 up to 1,347,425 shares of Common Stock underlying pre-funded warrants issued pursuant to
 a private placement transaction with Mr. Sixsmith.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Based
 solely on a Schedule 13G filed by Off the Chain LP ("OTC") with the SEC on October
 1, 2024, reporting on beneficial ownership as of September 25, 2024. OTC's address
 is listed on the Schedule 13G as 10337 Los Feliz Dr., Orlando, Florida 32836.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Based
 solely on a Schedule 13G filed by TD Securities (USA) LLC ("TD Securities") with
 the SEC on February 14, 2025, reporting on beneficial ownership as of December 31, 2024.
 TD Securities' address is listed on the Schedule 13G as 1 Vanderbilt Ave., New York,
 New York 10017.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Includes
 15,956 shares underlying warrants related to the Pre-Closing PIPE and the Warrant Agreements
 executed at the closing of the business combination with Data Knights Acquisition Corp. in November 2023 (the "Business Combination"). Also includes 345,000
 shares underlying vested RSUs or RSUs vesting within 60 days of October 23, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Includes
 an aggregate of 37,862 shares underlying warrants related to (i) the Pre-Closing
 PIPE and the Warrant Agreements executed at the closing of the Business Combination and
 (ii) public warrants of the Company. Also includes 275,769 shares underlying vested
 RSUs or RSUs vesting within 60 days of October 23, 2025. Excludes (x) an aggregate
 of 1,145,484 shares held by the Jeffrey N.C. Yu Spousal Trust and the Wendy Sanderson Yu
 Spousal Trust and (y) an aggregate of 1,313,770 shares held by certain trusts of Dr. Yu's
 children, for which, in each case, Dr. Yu is not the trustee of the trusts
 and has no investment control over the shares held in the trusts. Dr. Yu disclaims beneficial
 ownership of the shares held in the trusts.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Includes
 31,916 shares underlying warrants related to the Pre-Closing PIPE and the Warrant Agreements
 executed at the closing of the Business Combination. Also includes 45,000 shares underlying
 vested RSUs or RSUs vesting within 60 days of October 23, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Mr.
 Casey retired from the Company in March 2024.

&nbsp;&nbsp;&nbsp;&nbsp;(8) Ms.
 Embree resigned from the Company in August 2024.

**Delinquent Section 16(a) Reports**

Section 16(a) of the Exchange Act requires our executive officers, directors, and people who own more than 10% of a registered class of our equity securities to file an initial report of ownership (on a Form 3) and reports on subsequent changes in ownership (on Forms 4 or 5) with the SEC by specified due dates. Our executive officers, directors, and greater-than-10% stockholders are also required by SEC rules to furnish us with copies of all Section 16(a) forms they file. As a matter of practice, our staff is assisting our executive officers and directors in preparing initial ownership reports and reporting ownership changes, and will file those reports on their behalf. We are required to disclose in this proxy statement any failure to file any of these reports on a timely basis. Based solely on our review of the copies of the forms filed electronically with the SEC, and on written representations from certain reporting persons, we believe that all of these requirements were satisfied during the year ended December 31, 2024, except for the following:

● Initial Statements of Beneficial Ownership of Securities on Form 3 for each of Andrew Zeinfeld (appointed effective August 14, 2024), Jair Clarke (appointed on October 1, 2024), and Sherry Coonse McCraw (appointed on October 1, 2024), in each case, upon their respective appointment to the Board.

● Statements of Changes of Beneficial Ownership of Securities on Form 4:

◌ For each of Andrew Zeinfeld, Jair Clarke, and Sherry Coonse McCraw, in each case, for initial equity award grants upon their respective appointment to the Board; and

---

| | |
|:---|:---|
| ◌ | For each of Dr. Jeffrey Yu (230,769 restricted stock units on October 1, 2024) and Robert Golden (100,000 restricted stock units on August 30, 2024), in each case, in connection with the grant of equity awards. |

---

**Equity Compensation Plan Information**

The table below summarizes information relating to our equity compensation plans at December 31, 2024.

---

| | | | |
|:---|:---|:---|:---|
| Plan category | Number of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted-average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in the first column) |
| Equity compensation plans approved by security holders<sup>(1)</sup> | 147000 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.00 | 1352736<sup>(1)(2)</sup> |
| Equity compensation plans not approved by security holders | – | – | – |
| Total | 147000 | $1.00 | 1352736 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) At
 the Special Meeting held on October 17, 2023, our stockholders considered and approved the
 OneMedNet Corporation 2022 Equity Incentive Plan and reserved for issuance thereunder an
 amount of shares of Common Stock equal to 10% of the number of shares of Common Stock of
 the Company following the Business Combination. The Business Combination closed on November
 7, 2023. All prior equity plans were cancelled in connection with the closing of the Business
 Combination.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The
 2022 Plan allows for the issuance of options, stock appreciation rights, restricted stock,
 restricted stock units, performance awards and other equity awards.

**Certain Relationships and Related-Person Transactions**

**Related Person Transactions**

The following is a description of certain transactions, arrangements and relationships in which we were a participant since January 1, 2023 and the amount involved exceeded or will exceed $120,000, and in which any of our executive officers, directors or holders of more than 5% of any class of our voting securities, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. Certain equity, compensation, and other arrangements are described under "Executive Compensation" and are not considered related person transactions for these purposes.

*PIPE Notes and Warrants*

As disclosed in Note 3 and Note 7 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, Data Knights issued and sold PIPE Notes in connection with the Business Combination, which are convertible into shares of Common Stock. Total proceeds raised from the PIPE Notes were $1.5 million, of which $1.0 million were with related party investors, including Mr. Green (our Chief Executive Officer), Dr. Yu (our Chairman of the Board) and Dr. Kosasa (a director). In connection with the issuance of the PIPE Notes, the Company also issued a total of 95,744 shares of PIPE Warrants, of which 63,829 shares were issued to the same related party investors. Refer to Note 12 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for additional details on the terms of the PIPE Warrants.

On June 17, 2025 and June 19, 2025, the holders of approximately $1.66 million of Pre-Closing PIPE Notes (including Mr. Green, Dr. Yu and Dr. Kosasa) delivered notices to the Company of their respective elections to convert in full the amounts of outstanding amounts under the PIPE Notes (the "PIPE Notes Conversion"). Under the PIPE Notes Conversion, the Company issued an aggregate of 1,453,174 shares of Common Stock in full satisfaction of the PIPE Notes. The PIPE Notes were converted pursuant to their terms at a conversion price of $1.14 per shares.

 

*Convertible Promissory Notes and Warrants*

From 2019 to 2023, the Company issued various Convertible Promissory Notes to related party investors. Total gross proceeds raised from Convertible Promissory Notes with related parties was $12.3 million (out of $14.2 million total). In connection with the issuance of the Convertible Promissory Notes, the Company also issued 2,976,000 shares of Convertible Promissory Note Warrants to the same related parties (out of 3,726,000 total). Refer to Note 7 and Note 12 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 for additional details on the terms of the Convertible Promissory Notes and Convertible Promissory Note Warrants, respectively.

The Closing of the Business Combination triggered the conversion of all Convertible Promissory Notes into shares of Common Stock, as disclosed in Note 3 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.

*Shareholder Loans*

 

From April 2023 to December 2023, the Company entered into shareholder loans with two related party investors, including Dr. Yu (our Chairman of the Board) and Dr. Kosasa (a director) (the "Shareholder Loans") for aggregate gross proceeds of $954 thousand. The Shareholder Loans bear an interest rate of 8.0% and mature one year from issuance. There are no financial or non-financial covenants associated with the Shareholder Loans. The Shareholder Loans are not convertible into equity.

On November 7, 2023, in connection with the Business Combination, one of the Shareholder Loans for $0.5 million was converted into a PIPE Note equal to the amount of principal and interest outstanding at the time of Closing. The Company accounted for the exchange as an extinguishment whereby the Shareholder Loan was written off and a separate PIPE Note was recorded at fair value, as disclosed in Note 7 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.

During 2024, through the date of this report, the Company received gross proceeds of $2.0 million in connection with shareholder loans with related party investors, including Dr. Yu (our Chairman of the Board) and Dr. Kosasa (a director). Of the $2.0 million, $1.6 million is convertible into shares of Common Stock at a conversion price of $0.7535 per share. The remaining $0.4 million is not convertible into equity and bears an interest rate of 8.0% with a maturity date one year from issuance. The Company subsequently repaid $0.2 million of the non-convertible shareholder loans to Dr. Yu.

*Loan Extensions*

 

As disclosed in Note 3 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, in connection with the Business Combination, the Company assumed Data Knights' liabilities, which included existing loan extensions to related parties. The loan extensions were to be exchanged for a fixed amount of the Company's Common Stock upon the closing of a business combination or a similar event. As of December 31, 2024, a balance of $3.0 million remains outstanding and is recorded as loan extensions on the Company's consolidated balance sheet.

 

*Debt Reductions*

On June 19, 2025, the Company entered into agreements with Dr. Kosasa and Dr. Yu to convert an aggregate of approximately $3.3 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans referenced above (collectively, the "Loans") made by Dr. Kosasa and Dr. Yu to the Company into an aggregate of 4,693,296 shares of Common Stock (the "Loan Conversions"). The Loans were converted at a conversion price of $0.71 per share. Pursuant to Loan Conversions, (i) Dr. Kosasa converted Loans with aggregate principal and accrued interest of approximately $2.0 million for 2,865,016 shares of Common Stock, and (ii) Dr. Yu converted Loans with aggregate principal and accrued interest of approximately $1.3 million for 1,828,280 shares of Common Stock.

On June 19, 2025, Dr. Kosasa delivered notice to the Company of his election to convert in full the amounts of outstanding principal under certain convertible shareholder loans (the "Kosasa Convertible Loans") previously made by Dr. Kosasa to the Company, in an aggregate principal amount of approximately $1.6 million, converting into an aggregate of 2,123,424 shares of Common Stock (the "Kosasa Convertible Loan Conversions"). The Kosasa Convertible Loans were converted pursuant to their terms at a conversion price of $0.7535 per share.

*Other Private Placements*

 ****

On June 20, 2025, the Company entered into subscription agreements with each of Dr. Kosasa (the "Kosasa Investment"), and Dr. Yu (the "Yu Investment"). Pursuant to the Kosasa Investment, the Company agreed to issue and sell 1,190,476 shares of Common Stock at a purchase price of $0.42 per share, totaling $500,000 in gross proceeds to the Company. Pursuant to the Yu Investment, the Company agreed to issue and sell 1,666,666 shares of Common Stock at a purchase price of $0.42 per share, totaling $700,000 in gross proceeds to the Company.

On August 29, 2025, the Company entered into a subscription agreement with Dr. Kosasa, pursuant to which the Company agreed to issue and sell 581,395 shares of Common Stock at a purchase price of $0.86 per share, totaling $500,000 in gross proceeds to the Company.

**Policies and Procedures for Approving Transactions with Related Persons**

Our Audit Committee reviews and oversees all related person transactions in accordance with our Related Party Transactions Policy, either in advance or when we become aware of a related person transaction that was not reviewed and approved in advance. Other than as described above, there were no related person transactions in the years ended December 31, 2023 or 2024. The transactions described above were approved by the Board at the time they were entered into.

**Householding**

We have adopted a practice called "householding." This practice allows us to deliver only one copy of certain of our stockholder communications (such as the Notice regarding the internet availability of proxy materials, our annual reports, or our proxy materials) to stockholders who have the same address and last name and who do not participate in email delivery of these materials, unless one or more of these stockholders notifies us that he or she would like to receive an individual copy of these notices or materials. If you share an address with another stockholder and receive only one set of proxy-related materials and would like to request a separate copy for this year's Annual Meeting or for any future meetings or stockholder communications, please send your written request to OneMedNet Corporation, 6385 Old Shady Oak Road, Suite 250, Eden Prairie, Minnesota 55344, Attention: Corporate Secretary, or call us at (800) 918-7189. Upon written or oral request, we will promptly deliver a separate copy to you. Similarly, you may also contact us through either of these methods if you receive multiple copies of proxy-related materials and other stockholder communications and would prefer to receive a single copy in the future.

**Stockholder Proposals**

A stockholder who would like to have a proposal considered for inclusion in our 2026 proxy statement pursuant to SEC Rule 14a-8 must submit the proposal so that it is received by us no later than July 10, 2026, unless the date of our 2026 Annual Meeting is more than 30 days before or after December 17, 2026, in which case the proposal must be received a reasonable time before we begin to print and send our proxy materials. SEC rules set standards for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement. Stockholder proposals should be addressed to the Corporate Secretary, OneMedNet Corporation, 6385 Old Shady Oak Road, Suite 250, Eden Prairie, Minnesota 55344.

For stockholder proposals submitted outside of the SEC proposal rules, our Bylaws require that advance written notice in proper form of stockholder proposals for matters to be brought before an annual meeting be received by our Corporate Secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day before the anniversary date of the immediately preceding annual meeting. Accordingly, notice of stockholder proposals for the 2026 Annual Meeting of Stockholders must be received by us between August 19, 2026 and September 18, 2026. If the date of the 2026 Annual Meeting of Stockholders is more than 30 days before or 60 days after December 17, 2026, we must receive the proposal or nomination not earlier than the close of business on the 120th day before the annual meeting date and not later than the later of the close of business on the 90th day before the annual meeting date or the close of business on the 10th day following the day on which public announcement of the date of the annual meeting is made.

In addition to satisfying the notice requirements under our Bylaws, to comply with the universal proxy rules, the proposing stockholder should also comply with the additional requirements of a proper notice under SEC Rule 14a-19, which includes the statement that such stockholder intends to solicit at least 67% of the voting power of our shares of common stock entitled to vote on the election of directors in support of director nominees other than our nominees. If any change occurs with respect to such stockholder's intent to solicit the holders of shares representing at least 67% of such voting power, such stockholder must notify us promptly

**Annual Report on Form 10-K and Other SEC Filings**

**At your request, we will provide you with a copy of our Annual Report on Form 10-K for the year ended December 31, 2024, without charge. You should send your written requests to the attention of our Corporate Secretary, OneMetNed Corporation, 6385 Old Shady Oak Road, Suite 250, Eden Prairie, Minnesota 55344. The exhibits to the annual report are available upon payment of charges that approximate our cost of reproduction.**

You can also obtain copies of the annual report and exhibits, as well as other filings that we make with the SEC, on our website at https://www.onemednet.com/investor-relations/ or on the SEC's website at https://www.sec.gov/.

**Other Matters**

The Board does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this proxy statement are properly brought before the Annual Meeting, the individuals named in the enclosed proxy intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment on those matters.

---

| |
|:---|
| By Order of the Board of Directors, |
| /s/ Aaron Green |
| Aaron Green<br> Chief Executive Officer |

---

November 7, 2025

![](formdef14a_002.jpg)

![](formdef14a_003.jpg)